| Open: Vedolizumab for ulcerative colitis: treatment outcomes from the VICTORY consortium N Narula, F Peerani, J Meserve, G Kochhar, K Chaudrey, J Hartke, ... Official journal of the American College of Gastroenterology| ACG 113 (9), 1345, 2018 | 146 | 2018 |
| Development and validation of a scoring system to predict outcomes of vedolizumab treatment in patients with Crohn’s disease PS Dulai, BS Boland, S Singh, K Chaudrey, JL Koliani-Pace, G Kochhar, ... Gastroenterology 155 (3), 687-695. e10, 2018 | 127 | 2018 |
| Retrospective analysis of safety of vedolizumab in patients with inflammatory bowel diseases J Meserve, S Aniwan, JL Koliani-Pace, P Shashi, A Weiss, D Faleck, ... Clinical Gastroenterology and Hepatology 17 (8), 1533-1540. e2, 2019 | 84 | 2019 |
| Provider attitudes and practices for alcohol screening, treatment, and education in patients with liver disease: a survey from the American Association for the Study of Liver … GY Im, JL Mellinger, A Winters, ES Aby, Z Lominadze, J Rice, MR Lucey, ... Clinical Gastroenterology and Hepatology 19 (11), 2407-2416. e8, 2021 | 64 | 2021 |
| Development and validation of clinical scoring tool to predict outcomes of treatment with vedolizumab in patients with ulcerative colitis PS Dulai, S Singh, NV Casteele, J Meserve, A Winters, S Chablaney, ... Clinical Gastroenterology and Hepatology 18 (13), 2952-2961. e8, 2020 | 59 | 2020 |
| Shorter disease duration is associated with higher rates of response to vedolizumab in patients with Crohn’s disease but not ulcerative colitis DM Faleck, A Winters, S Chablaney, P Shashi, J Meserve, A Weiss, ... Clinical Gastroenterology and Hepatology 17 (12), 2497-2505. e1, 2019 | 55 | 2019 |
| Comparative safety and effectiveness of vedolizumab to tumour necrosis factor antagonist therapy for Crohn's disease M Bohm, R Xu, Y Zhang, S Varma, M Fischer, G Kochhar, B Boland, ... Alimentary Pharmacology & Therapeutics 52 (4), 669-681, 2020 | 53 | 2020 |
| Comparative safety and effectiveness of vedolizumab to tumor necrosis factor antagonist therapy for ulcerative colitis D Lukin, D Faleck, R Xu, Y Zhang, A Weiss, S Aniwan, S Kadire, G Tran, ... Clinical Gastroenterology and Hepatology 20 (1), 126-135, 2022 | 41 | 2022 |
| Hepatic encephalopathy challenges, burden, and diagnostic and therapeutic approach B Yanny, A Winters, S Boutros, S Saab Clinics in Liver Disease 23 (4), 607-623, 2019 | 30 | 2019 |
| A review of the use of transient elastography in the assessment of fibrosis and steatosis in the post–liver transplant patient AC Winters, R Mittal, TD Schiano Clinical Transplantation 33 (10), e13700, 2019 | 28 | 2019 |
| OP025 Comparative effectiveness of vedolizumab and tumour necrosis factor-antagonist therapy in Crohn’s disease: a multicentre consortium propensity score-matched analysis M Bohm, SV Sagi, M Fischer, S Kadire, G Tran, M Rahal, S Aniwan, ... Journal of Crohn's and Colitis 12 (supplement_1), S018-S018, 2018 | 28* | 2018 |
| OP026 Comparative effectiveness of vedolizumab and TNF-antagonist therapy in ulcerative colitis: a multicentre consortium propensity score-matched analysis D Faleck, P Shashi, J Meserve, M Rahal, S Kadire, G Tran, A Weiss, ... Journal of Crohn's and Colitis 12 (supplement_1), S019-S019, 2018 | 20 | 2018 |
| DOP009 Comparative safety profile of vedolizumab and tumour necrosis factor–antagonist therapy for inflammatory bowel disease: a multicentre consortium propensity score-matched … D Lukin, A Weiss, S Aniwan, S Kadire, G Tran, M Rahal, D Faleck, ... Journal of Crohn's and Colitis 12 (supplement_1), S036-S036, 2018 | 15* | 2018 |
| Splanchnic vein thrombosis associated with myeloproliferative neoplasms D Tremblay, A Winters, JD Beckman, L Naymagon, R Patel, ... Thrombosis Research 218, 8-16, 2022 | 14 | 2022 |
| A telephone and mail outreach program successfully increases uptake of hepatocellular carcinoma surveillance ES Aby, AC Winters, J Lin, A Bui, J Kawamoto, MB Goetz, D Bhattacharya, ... Hepatology communications 4 (6), 825-833, 2020 | 12 | 2020 |
| Reassessing the safety concerns of utilizing blood donations from patients with hemochromatosis AC Winters, D Tremblay, S Arinsburg, J Mascarenhas, TD Schiano Hepatology 67 (3), 1150-1157, 2018 | 12 | 2018 |
| 277-Comparative safety profile of vedolizumab and tumor necrosis factor-antagonist therapy for inflammatory bowel disease: a multicenter consortium propensity score-matched … DJ Lukin, A Weiss, S Aniwan, S Kadire, G Tran, M Rahal, D Faleck, ... Gastroenterology 6 (154), S-68, 2018 | 12 | 2018 |
| Changes in vedolizumab utilization across US academic centers and community practice are associated with improved effectiveness and disease outcomes JL Koliani-Pace, S Singh, M Luo, R Hirten, S Aniwan, G Kochhar, ... Inflammatory bowel diseases 25 (11), 1854-1861, 2019 | 10 | 2019 |
| The novel SALT-M score predicts 1-year post-transplant mortality in patients with severe acute-on-chronic liver failure R Hernaez, CJ Karvellas, Y Liu, SC Sacleux, S Khemichian, LL Stein, ... Journal of Hepatology 79 (3), 717-727, 2023 | 9 | 2023 |
| Management of side effects of systemic therapies for hepatocellular carcinoma: guide for the hepatologist AC Winters, F Bedier, S Saab Clinics in Liver Disease 24 (4), 755-769, 2020 | 9 | 2020 |
